RIO DE JANEIRO, BRAZIL - A candidate for coronavirus vaccine has achieved successful results against the most common mutation of the virus - and may expedite the development of a cure.
According to a new study, the product manufactured by the Moderna biotech company has been tested for the D614G mutation of the virus, present in over 70 percent of confirmed infections worldwide. It is also the most common strain in Europe, reaching 100 percent of cases in some countries.
The research was led by Professor Drew Weissman from the University of Pennsylvania and published on Medrxiv.org but has not yet . . .